The relation of sTRAIL levels and quality of life in severe persistent allergic asthma patients using omalizumab

Medical Science Monitor

Volumn 18, Issue 8, 2012, Pages

  Yalcin, Arzu Didem ^a   Bisgin, Atil ^a  

^a Antalya EGitim Ve Arastirma Hastanesi Varlik Mahallesi Kazim Karabekir Caddesi SoGuksu   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

OMALIZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ALLERGIC ASTHMA; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFECT; EDITORIAL; HUMAN; LUNG FUNCTION; QUALITY OF LIFE;

EID: 84866111954     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/msm.883249     Document Type: Editorial

References (10)

1. Ayres JG, Higgins B, Chilvers ER et al: Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy, 2004; 59(7): 701-8
2. Robertson NM, Zangrilli JG, Steplewski A et al: Differential Expression of TRAIL and TRAIL Receptors in Allergic Asthmatics Following Segmental Antigen Challenge: Evidence for a Role of TRAIL in Eosinophil Survival. J Immunol, 2002; 169(10): 5986-96
3. Chaudhari BR, Murphy RF, Agrawal DK: Following the TRAIL to apoptosis. Immunol Res, 2006; 35(3): 249-62
4. Yalcin AD, Bisgin A, Kargi A, Gorczynski RM: Serum soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to Omalizumab treatment. Med Sci Monit, 2012; 18(3): PI11-15
5. Bousquet J, Wenzel S, Holgate S et al: Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest, 2004; 125: 1378-86
6. Eckman JA, Sterba PM, Kelly D et al: Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. J Allergy Clin Immunol, 2010; 125
7. MacGlashan DW Jr, Bochner BS, Adelman DC et al: Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol, 1997; 158: 1438-45
8. Yalcin AD: The therapeutic efficacy and side effect of omalizumab. Respirology, 2011; 16(2): 192
9. Yalcin AD, Gorczynski RM, Parlak GE et al: Total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in patients with severe persistent allergic asthma: its relation to omalizumab treatment. Clin Lab, 2012; 58(1-2): 89-96
10. Yalcin AD, Gumuslu S, Bisgin A et al: Systemic Levels Of Ceruloplasmin Oxidase Activity In Allergic Asthma And Allergic Rhinitis. Immunopharmacol Immunotoxicol, 2012